$0.18 EPS Expected for Medidata Solutions, Inc. (MDSO)

January 13, 2018 - By Marry Poplack

 $0.18 EPS Expected for Medidata Solutions, Inc. (MDSO)
Investors sentiment increased to 1.23 in Q3 2017. Its up 0.06, from 1.17 in 2017Q2. It is positive, as 38 investors sold Medidata Solutions, Inc. shares while 60 reduced holdings. 33 funds opened positions while 88 raised stakes. 59.30 million shares or 4.96% more from 56.50 million shares in 2017Q2 were reported.
Yorktown And Rech Co accumulated 4,600 shares or 0.09% of the stock. Com Bancorporation invested 0.01% of its portfolio in Medidata Solutions, Inc. (NASDAQ:MDSO). Denver Investment Advisors Ltd Com holds 10,345 shares or 0.04% of its portfolio. Redwood Lc has invested 0.68% in Medidata Solutions, Inc. (NASDAQ:MDSO). Hartwell J M Ltd Partnership invested in 7,400 shares. Oregon Employees Retirement Fund holds 0.03% or 20,438 shares in its portfolio. Stevens Capital Lp holds 0.02% of its portfolio in Medidata Solutions, Inc. (NASDAQ:MDSO) for 6,523 shares. Price T Rowe Incorporated Md reported 0% stake. Blackrock Inc reported 6.60M shares or 0.03% of all its holdings. Moreover, Glenmede Tru Na has 0% invested in Medidata Solutions, Inc. (NASDAQ:MDSO) for 1,073 shares. Tocqueville Asset Mngmt L P stated it has 0.01% of its portfolio in Medidata Solutions, Inc. (NASDAQ:MDSO). 829 are owned by Group Inc One Trading Limited Partnership. Legal General Grp Public Ltd Co has 0% invested in Medidata Solutions, Inc. (NASDAQ:MDSO) for 50,575 shares. Aperio Group Inc Limited Liability Co owns 0.01% invested in Medidata Solutions, Inc. (NASDAQ:MDSO) for 12,848 shares. American Capital Mgmt stated it has 357,548 shares or 1.74% of all its holdings.

Since August 15, 2017, it had 0 buys, and 2 sales for $504,550 activity. $372,650 worth of Medidata Solutions, Inc. (NASDAQ:MDSO) shares were sold by Capone Michael L.

Analysts expect Medidata Solutions, Inc. (NASDAQ:MDSO) to report $0.18 EPS on February, 8.They anticipate $0.05 EPS change or 21.74 % from last quarter’s $0.23 EPS. MDSO’s profit would be $10.53M giving it 92.92 P/E if the $0.18 EPS is correct. After having $0.22 EPS previously, Medidata Solutions, Inc.’s analysts see -18.18 % EPS growth. The stock increased 1.61% or $1.06 during the last trading session, reaching $66.9. About 423,310 shares traded. Medidata Solutions, Inc. (NASDAQ:MDSO) has risen 68.37% since January 13, 2017 and is uptrending. It has outperformed by 51.67% the S&P500.

Medidata Solutions, Inc. (NASDAQ:MDSO) Ratings Coverage

Among 17 analysts covering Medidata Solutions Inc. (NASDAQ:MDSO), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Medidata Solutions Inc. has $92.0 highest and $35 lowest target. $76.50’s average target is 14.35% above currents $66.9 stock price. Medidata Solutions Inc. had 38 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Medidata Solutions, Inc. (NASDAQ:MDSO) has “Overweight” rating given on Thursday, July 20 by Morgan Stanley. The stock of Medidata Solutions, Inc. (NASDAQ:MDSO) earned “Hold” rating by Jefferies on Tuesday, July 18. The firm has “Buy” rating given on Thursday, February 11 by Needham. The stock has “Buy” rating by Needham on Monday, October 23. As per Wednesday, October 28, the company rating was maintained by Stifel Nicolaus. Morgan Stanley maintained Medidata Solutions, Inc. (NASDAQ:MDSO) on Wednesday, June 14 with “Buy” rating. As per Thursday, September 28, the company rating was maintained by Jefferies. As per Thursday, October 26, the company rating was maintained by Piper Jaffray. The rating was upgraded by Topeka Capital Markets to “Buy” on Wednesday, October 28. As per Monday, November 13, the company rating was upgraded by Dougherty.

Medidata Solutions, Inc. provides cloud solutions for life sciences worldwide. The company has market cap of $3.91 billion. It offers Medidata Clinical Cloud that provides a software-as-a-service platform of technology and data analytics solutions to optimize activities across clinical development. It has a 95.71 P/E ratio. The companyÂ’s platform solutions includes Plan Study that addresses the areas to ensure optimal study design, grant development and negotiation, and investigator payments; and Support Sites, which provides robust risk management, reduced source document verification, real-time monitoring, on-time, accurate payments.

Another recent and important Medidata Solutions, Inc. (NASDAQ:MDSO) news was published by Seekingalpha.com which published an article titled: “Medidata Solutions’ (MDSO) CEO Tarek Sherif on Q3 2017 Results – Earnings Call …” on October 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: